Dr. Olowokure is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
7675 Wellness Way
West Chester, OH 45069Phone+1 513-475-8500Fax+1 513-584-4281
Education & Training
- Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 2006 - 2009
- St John's Episcopal Hospital-South ShoreResidency, Internal Medicine, 2002 - 2005
- University of Maiduguri College of Medical SciencesClass of 1997
Certifications & Licensure
- OH State Medical License 2009 - 2026
- NY State Medical License 2006 - 2011
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma Start of enrollment: 2011 Jul 19
- Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer Start of enrollment: 2011 Apr 07
- Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer Start of enrollment: 2012 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 15 citationsCarboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer.Stephanie Jeske, Scott T. Tagawa, Olugbenga Olowokure, Jodi Selzer, Paraskevi Giannakakou
Urologic Oncology. 2011-11-01 - 20 citationsMulticenter, randomized, double‐blind phase 2 trial of FOLFIRI with regorafenib or placebo as second‐line therapy for metastatic colorectal cancerHanna K. Sanoff, Richard M. Goldberg, Anastasia Ivanova, Seamus O'Reilly, Samer S. Kasbari
Cancer. 2018-08-01 - 14 citationsEnhanced Efficacy of Combination of Gemcitabine and Phosphatidylserine-Targeted Nanovesicles against Pancreatic Cancer.Kombo F. N’Guessan, Harold W. Davis, Zhengtao Chu, Subrahmanya D. Vallabhapurapu, Clayton S. Lewis
Molecular Therapy. 2020-08-05
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: